



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/694,534
	Filing Date	October 27, 2003
	First Named Inventor	Alex Aronov et al.
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-114 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
CA	A1	3,816,121	06/11/1974	Shiba et al.	96	97	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
CA	B1	WO 03/068743 A1	Astrazeneca AB	August 21, 2003		
CA	B2	WO 03/063797 A2	Bristol-Myers Squibb Company	August 7, 2003		
CA	B3	WO 03/040096 A2	Elan Pharmaceuticals, Inc. et al.	May 15, 2003		
CA	B4	WO 03/024962 A1	Astrazeneca AB	March 27, 2003		
CA	B5	EP 0 075 808 A2	Bayer AG	April 6, 1983		X
CA	B6	DE 25 33 958 A1	Hoechst AG	February 17, 1977		X
CA	B7	FR 1 516 610	Ferrania SPA	March 8, 1968		X
CA	B8	EP 1 199 306 A1	Banyu Pharmaceutical Co. Ltd.	April 24, 2002		
CA	B9	WO 03/078402 A1	Aventis Pharma S.A.	September 25, 2003		X
CA	B10	WO 98/24771 A1	Fujisawa Pharmaceutical Co., Ltd.	June 11, 1998		
CA	B11	EP 1 256 574 A1	Kirin Beer Kabushiki Kaisha	November 13, 2002		
CA	B12	EP 1 380 576 A1	Eisai Co., Ltd.	January 14, 2004		
CA	B13	WO 02/062795	Mitsubishi Pharma Corporation	August 15, 2002		
CA	B14	JP 2001-354511	Fuji Photo Film Co., Ltd.	December 25, 2001		X
CA	B15	JP 3-179345	Konica Co.	August 5, 1991		X
CA	B16	JP 3-150560	Konica Co.	June 26, 1991		X

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
CA	C1	File Chemical Abstracts, STN Caesar accession number: 1189, AN 52:25500.
CA	C2	File Chemical Abstracts, STN Caesar accession number: 1146, AN 132:122591.
CA	C3	Cui et al. "Non-covalent Thrombin Inhibitors Featuring P ₂ -Heterocycles with P ₁ -Bicyclic Arginine Surrogates", Bioorganic & Medicinal Chemistry Letters: 12 2925-2930 (2002).
CA	C4	Duman, "Protein Kinase Inhibitors: Emerging Pharmacophores 1997-2001", Exp. Opin. Ther. Patents 11(3): 405-429 (2001).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<u>AWLAKH</u>	Date Considered	<u>7/14/06</u>
--------------------	---------------	-----------------	----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.